Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLC-3010 in Advanced Solid Tumors
NCT05525247Phase 2Terminated
- Sponsor
- Selecxine
- Start
- Dec 2022
- Primary completion
- Aug 2025
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of SLC-3010 in solid tumor (advanced stage) (2 arms), sponsored by Selecxine. Primary endpoint: Dose-Limiting Toxicities at 30 days. Started Dec 2022; status: terminated.
02
Drugs
SLC-3010
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05525247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05525247.